The 36-month beta value for URGN is at 0.53. Analysts have varying views on the stock, with 5 analysts rating it as a “buy,” 2 rating it as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for URGN is 39.62M, and currently, shorts hold a 9.88% of that float. The average trading volume for URGN on June 24, 2025 was 2.71M shares.
URGN) stock’s latest price update
UroGen Pharma Ltd (NASDAQ: URGN) has seen a rise in its stock price by 1119988 in relation to its previous close of 14.3. However, the company has experienced a -3.91% decline in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-23 that NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASDAQ: URGN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
URGN’s Market Performance
UroGen Pharma Ltd (URGN) has experienced a -3.91% fall in stock performance for the past week, with a 237.75% rise in the past month, and a 15.80% rise in the past quarter. The volatility ratio for the week is 8.30%, and the volatility levels for the past 30 days are at 12.95% for URGN. The simple moving average for the past 20 days is 59.20% for URGN’s stock, with a 26.17% simple moving average for the past 200 days.
Analysts’ Opinion of URGN
Many brokerage firms have already submitted their reports for URGN stocks, with H.C. Wainwright repeating the rating for URGN by listing it as a “Buy.” The predicted price for URGN in the upcoming period, according to H.C. Wainwright is $50 based on the research report published on June 16, 2025 of the current year 2025.
Scotiabank gave a rating of “Sector Outperform” to URGN, setting the target price at $23 in the report published on April 16th of the current year.
URGN Trading at 50.05% from the 50-Day Moving Average
After a stumble in the market that brought URGN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -24.08% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at URGN starting from Schoenberg Mark, who sale 5,162 shares at the price of $7.37 back on Jun 09 ’25. After this action, Schoenberg Mark now owns 153,378 shares of UroGen Pharma Ltd, valued at $38,044 using the latest closing price.
Stock Fundamentals for URGN
Current profitability levels for the company are sitting at:
- -1.18 for the present operating margin
- 0.9 for the gross margin
The net margin for UroGen Pharma Ltd stands at -1.51. The total capital return value is set at -0.53.
Based on UroGen Pharma Ltd (URGN), the company’s capital structure generated 1.59 points at debt to capital in total, while cash flow to debt ratio is standing at -0.86. The debt to equity ratio resting at -2.69. The interest coverage ratio of the stock is -17.97.
Currently, EBITDA for the company is -110.33 million with net debt to EBITDA at -0.21. When we switch over and look at the enterprise to sales, we see a ratio of 7.13. The receivables turnover for the company is 4.68for trailing twelve months and the total asset turnover is 0.37. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.65.
Conclusion
In conclusion, UroGen Pharma Ltd (URGN) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
